Professional
Added to YB: 2024-11-27
Pitch date: 2024-11-11
NTLA [bullish]
Intellia Therapeutics, Inc.
-46.82%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.
Market Cap
$1.0B
Pitch Price
$17.15
Price Target
85.00 (+832%)
Dividend
N/A
EV/EBITDA
-1.03
P/E
-2.05
EV/Sales
7.58
Sector
Biotechnology
Category
growth
Show full summary:
Intellia Therapeutics, Inc.: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors
NTLA: Early-stage gene editing pipeline progressing. FV $85. NTLA-2002 Phase 3 for HAE (35% approval prob), potential 2028 launch. NTLA-2001 Phase 3 for ATTR (40% prob), possible 2026 launch, $1B sales by 2034. $944M cash runway to late 2026. High R&D costs near-term.
Read full article (11 min)